{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:33:21Z","timestamp":1793226801008,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgery"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.surg.2026.110526","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T23:28:52Z","timestamp":1786404532000},"page":"110526","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["[18F]-Fluorodeoxyglucose positron emission tomography in grade 1\u20132 pancreatic neuroendocrine tumors: Prognostic in grade 2, not predictive of systemic therapy benefit"],"prefix":"10.1016","volume":"199","author":[{"given":"Kunal","family":"Nandy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Parray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indraja","family":"Dev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishnu","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameya","family":"Puranik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatesh","family":"Rangarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Parghane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Ostwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anant","family":"Ramaswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swara","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish S.","family":"Bhandare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8033-0277","authenticated-orcid":false,"given":"Vikram A.","family":"Chaudhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailesh V.","family":"Shrikhande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.surg.2026.110526_bib1","first-page":"471","article-title":"Gastroenteropancreatic neuroendocrine tumors","volume":"68","author":"Cives","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.surg.2026.110526_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179445","article-title":"Impact of Ki67 re-assessment at time of disease progression in patients with pancreatic neuroendocrine neoplasms","volume":"12","author":"Panzuto","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.surg.2026.110526_bib3","series-title":"Digestive System Tumours. WHO Classification of Tumours","year":"2022"},{"key":"10.1016\/j.surg.2026.110526_bib4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1159\/000494355","article-title":"Competitive testing of the WHO 2010 versus the WHO 2017 grading of pancreatic neuroendocrine neoplasms: data from a large international cohort study","volume":"107","author":"Rindi","year":"2019","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.surg.2026.110526_bib5","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/endocrines2010003","article-title":"Tumor heterogenity in gastro-entero-pancreatic neuroendocrine neoplasia","volume":"2","author":"Magi","year":"2021","journal-title":"Endocrines"},{"key":"10.1016\/j.surg.2026.110526_bib6","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s12020-017-1364-8","article-title":"KI-67 heterogeneity in well differentiated gastro-entero-pancreatic neuroendocrine tumors: when is biopsy reliable for grade assessment?","volume":"57","author":"Grillo","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.surg.2026.110526_bib7","doi-asserted-by":"crossref","first-page":"808","DOI":"10.2967\/jnumed.120.244798","article-title":"18F-FDG-PET is superior to WHO grading as prognostic tool in neuroendocrine neoplasms and useful in guiding peptide receptor radionuclide therapy: a prospective 10-year follow-up study of 166 patients","volume":"62","author":"Binderup","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.surg.2026.110526_bib8","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s40618-025-02552-1","article-title":"Clinical and biological heterogeneity of grade 2 digestive neuroendocrine neoplasms: prognostic significance of the 10% Ki-67 index cutoff","volume":"48","author":"Massironi","year":"2025","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.surg.2026.110526_bib9","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1634\/theoncologist.2017-0278","article-title":"Clinical usefulness of 18F-fluorodeoxyglucose positron emission tomography in the diagnostic algorithm of advanced entero-pancreatic neuroendocrine neoplasms","volume":"23","author":"Rinzivillo","year":"2018","journal-title":"The Oncologist"},{"key":"10.1016\/j.surg.2026.110526_bib10","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13343","article-title":"European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours","volume":"35","author":"Kos-Kud\u0142a","year":"2023","journal-title":"J neuroendocrinology"},{"key":"10.1016\/j.surg.2026.110526_bib11","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s12020-022-03000-3","article-title":"Role of [18F] FDG PET\/CT in the management of G1 gastro-entero-pancreatic neuroendocrine tumors","volume":"76","author":"Magi","year":"2022","journal-title":"Endocrine"},{"key":"10.1016\/j.surg.2026.110526_bib12","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/jhbp.734","article-title":"Usefulness of 18F-FDG-PET\/CT in the diagnosis and prediction of recurrence of pancreatic neuroendocrine neoplasms","volume":"27","author":"Sato","year":"2020","journal-title":"J Hepato-Biliary-Pancreatic Sci"},{"key":"10.1016\/j.surg.2026.110526_bib13","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association declaration of helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.surg.2026.110526_bib14","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000471879","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine and hybrid imaging","volume":"105","author":"Sundin","year":"2017","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.surg.2026.110526_bib15","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/cncr.25425","article-title":"First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas","volume":"117","author":"Strosberg","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.surg.2026.110526_bib16","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00259-020-05004-5","article-title":"Long-term outcome of \"Sandwich\" chemo-PRRT: a novel treatment strategy for metastatic neuroendocrine tumors with both FDG- and SSTR-avid aggressive disease","volume":"48","author":"Parghane","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.surg.2026.110526_bib17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.surg.2026.110526_bib18","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s00259-014-2906-4","article-title":"Favourable outcomes of 177 Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours","volume":"42","author":"Kashyap","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.surg.2026.110526_bib19","doi-asserted-by":"crossref","first-page":"e676","DOI":"10.1097\/RLU.0000000000004365","article-title":"Impact of FDG PET\/CT Scan in changing management of well-differentiated neuroendocrine tumors with Ki67 index less than or equal to 5%","volume":"47","author":"Choudhury","year":"2022","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.surg.2026.110526_bib20","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000457954","article-title":"Bone metastases in patients with neuroendocrine neoplasm: frequency and clinical, therapeutic, and prognostic relevance","volume":"106","author":"Scharf","year":"2017","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.surg.2026.110526_bib21","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000508633","article-title":"Bone metastases in neuroendocrine tumors: molecular pathogenesis and implications in clinical practice","volume":"111","author":"Cives","year":"2021","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.surg.2026.110526_bib22","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s00259-016-3527-x","article-title":"High clinical and morphologic response using 90 Y-DOTA-octreotate sequenced with 177 Lu-DOTA-octreotate induction Peptide Receptor Chemoradionuclide Therapy (PRCRT) for bulky neuroendocrine tumours","volume":"44","author":"Kong","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.surg.2026.110526_bib23","first-page":"1012","article-title":"[18F]FDG metabolic tumor volume as a prognostic marker in neuroendocrine neoplasm: a multicenter study","volume":"66","author":"Chan","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1016\/j.surg.2026.110526_bib24","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s13139-013-0262-0","article-title":"Prognostic value of volume-based metabolic parameters measured by 18F-FDG PET\/CT of pancreatic neuroendocrine tumors","volume":"48","author":"Kim","year":"2014","journal-title":"Nucl Med Mol Imaging"}],"container-title":["Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039606026004514?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039606026004514?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:10:39Z","timestamp":1793225439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039606026004514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":24,"alternative-id":["S0039606026004514"],"URL":"https:\/\/doi.org\/10.1016\/j.surg.2026.110526","relation":{},"ISSN":["0039-6060"],"issn-type":[{"value":"0039-6060","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[18F]-Fluorodeoxyglucose positron emission tomography in grade 1\u20132 pancreatic neuroendocrine tumors: Prognostic in grade 2, not predictive of systemic therapy benefit","name":"articletitle","label":"Article Title"},{"value":"Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.surg.2026.110526","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110526"}}